Accelerating oncology breakthroughs
Next-generation oncology therapies bring more unknowns and more complex development. At IQVIA we recognize that your scientific breakthroughs deserve a new approach.
IQVIA brings innovation to the needs of today’s oncology development to help you deliver new, better medicines for cancer patients faster. By making intelligent connections, we help you focus on the patient, manage trial complexity, and increase predictability and speed.
Take your first step to accelerating your oncology advances by completing this form.
Please fill out the form to speak to an IQVIA oncology expert and learn more
Combinations Take Center Stage In PD1/PDL1 Inhibitor Clinical Trials
Anti-PD1/PDL1 monoclonal antibodies (mAbs) are paving the way to a new era of cancer care, having achieved the most success of existing immuno-oncology (IO) agents in clinical development. IQVIA and Cancer Research Institute collaborated on this report to examine the combination strategies in anti-PD1/PDL1 mAbs clinical trials.
Biomarker Testing in Oncology
Find out how Oncologists are making more informed treatment decisions by testing for predictive biomarkers that indicate a patient’s likelihood to respond to certain treatments
Accelerating oncology breakthroughs to help you deliver medicines for cancer patients faster
